First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
Completed · Phase 1 · Has a placebo group
Conditions studied: Viral Disease
In brief
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
Key facts
- Study ID
- NCT04535167
- Run by
- Pfizer
- People needed
- 26
- Starts
- 2020-09-09
- Expected to finish
- 2021-06-07
- Last updated by the study team
- 2023-05-03
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- El Camino Health — Mountain View, California, United States
- Palo Alto Medical Foundation — Mountain View, California, United States
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
- UC Davis Health Investigational Drug Pharmacy — Sacramento, California, United States
- UC Davis Medical Center — Sacramento, California, United States
- Massachusetts General Hospital Translational and Clinical Research Center — Boston, Massachusetts, United States
- Massachusetts General Hospital, Clinical Trials Pharmacy — Boston, Massachusetts, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Regional One Health — Memphis, Tennessee, United States
- University Hospital Brugmann — Brussels, Belgium
- Santa Casa De Misericórdia de Belo Horizonte — Belo Horizonte, Minas Gerais, Brazil
- Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
- Hospital Universitario Virgen Del Rocio — Seville, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.